Stent expansion in calcified coronary chronic total occlusions: The impact of different stent platforms.
bioabsorbable-polymer sirolimus-eluting stent
calcifications
coronary chronic total occlusions
durable-polymer everolimus-eluting stent
durable-polymer zotarolimus-eluting stent
stent expansion
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
23
06
2023
received:
12
02
2023
accepted:
09
07
2023
medline:
12
9
2023
pubmed:
1
8
2023
entrez:
1
8
2023
Statut:
ppublish
Résumé
To evaluate the stent expansion of the durable-polymer Zotarolimus-eluting stent (dp-ZES), the durable-polymer Everolimus-eluting stent (dp-EES), and the bioabsorbable-polymer Sirolimus-eluting stent (bp-SES) in calcified coronary chronic total occlusions (CTO). The newer generation stents with ultrathin struts might raise concerns regarding reduced radial strength and higher stent recoil (SR) when implanted in calcified CTOs. Between January 2017 and June 2021 consecutive patients with CTO undergoing percutaneous coronary intervention with dp-ZES, dp-EES, or bp-SES were evaluated. The analysis was performed in calcific and in noncalcific CTOs. Quantitative coronary angiography analysis was used to assess diameter stenosis (DS), absolute and relative SR, absolute and relative focal SR, absolute and relative balloon deficit (BD), and absolute and relative focal BD. The primary endpoint was DS. A total of 213 CTOs were evaluated, 115 calcific CTOs (dp-ZES:25, dp-EES:29, bp-SES:61) and 98 non-calcific CTOs (dp-ZES:41, dp-EES:11, bp-SES:46). In calcific CTOs, residual DS was lower in dp-ZES than in dp-EES and bp-SES (-1.00% [-6.50-6.50] vs. 13.00% [7.0-19.00] vs. 15.00% [5.00-20.00]; p < 0.001). Dp-ZES was also an independent predictor of residual DS ≤ 10% (OR 11.34, 95% CI 2.6-49.43, p = 0.001). Absolute and relative focal SR and absolute and relative SR were similar between dp-ZES, dp-EES, and bp-SES (p = 0.913, p = 0.890, p = 0.518, p = 0.426, respectively). In noncalcified CTOs, the residual DS was similar in the three groups (p = 0.340). High relative focal SR was less frequent in dp-ZES than in dp-EES and in bp-SES (19.5% vs. 54.5% vs. 37.0%; p < 0.048). The three stent platforms demonstrated an overall low residual DS when implanted in CTOs. However, dp-ZES was associated with the lowest residual DS and identified as independent predictor of residual DS ≤ 10% in patients with calcific CTOs. Dp-ZES was associated with a lower incidence of high relative focal stent recoil, in noncalcific CTOs. Balloon deficit might be considerate as a surrogate for stent expansion in calcified CTOs.
Sections du résumé
OBJECTIVES
To evaluate the stent expansion of the durable-polymer Zotarolimus-eluting stent (dp-ZES), the durable-polymer Everolimus-eluting stent (dp-EES), and the bioabsorbable-polymer Sirolimus-eluting stent (bp-SES) in calcified coronary chronic total occlusions (CTO).
BACKGROUND
The newer generation stents with ultrathin struts might raise concerns regarding reduced radial strength and higher stent recoil (SR) when implanted in calcified CTOs.
METHODS
Between January 2017 and June 2021 consecutive patients with CTO undergoing percutaneous coronary intervention with dp-ZES, dp-EES, or bp-SES were evaluated. The analysis was performed in calcific and in noncalcific CTOs. Quantitative coronary angiography analysis was used to assess diameter stenosis (DS), absolute and relative SR, absolute and relative focal SR, absolute and relative balloon deficit (BD), and absolute and relative focal BD. The primary endpoint was DS.
RESULTS
A total of 213 CTOs were evaluated, 115 calcific CTOs (dp-ZES:25, dp-EES:29, bp-SES:61) and 98 non-calcific CTOs (dp-ZES:41, dp-EES:11, bp-SES:46). In calcific CTOs, residual DS was lower in dp-ZES than in dp-EES and bp-SES (-1.00% [-6.50-6.50] vs. 13.00% [7.0-19.00] vs. 15.00% [5.00-20.00]; p < 0.001). Dp-ZES was also an independent predictor of residual DS ≤ 10% (OR 11.34, 95% CI 2.6-49.43, p = 0.001). Absolute and relative focal SR and absolute and relative SR were similar between dp-ZES, dp-EES, and bp-SES (p = 0.913, p = 0.890, p = 0.518, p = 0.426, respectively). In noncalcified CTOs, the residual DS was similar in the three groups (p = 0.340). High relative focal SR was less frequent in dp-ZES than in dp-EES and in bp-SES (19.5% vs. 54.5% vs. 37.0%; p < 0.048).
CONCLUSIONS
The three stent platforms demonstrated an overall low residual DS when implanted in CTOs. However, dp-ZES was associated with the lowest residual DS and identified as independent predictor of residual DS ≤ 10% in patients with calcific CTOs. Dp-ZES was associated with a lower incidence of high relative focal stent recoil, in noncalcific CTOs. Balloon deficit might be considerate as a surrogate for stent expansion in calcified CTOs.
Substances chimiques
Everolimus
9HW64Q8G6G
zotarolimus
H4GXR80IZE
Polymers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
451-463Informations de copyright
© 2023 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.
Références
Sakakura K, Nakano M, Otsuka F, et al. Comparison of pathology of chronic total occlusion with and without coronary artery bypass graft. Eur Heart J. 2014;35(25):1683-1693.
Morino Y, Abe M, Morimoto T, et al. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes. JACC Cardiovasc Interv. 2011;4(2):213-221.
Szijgyarto Z, Rampat R, Werner GS, et al. Derivation and validation of a chronic total coronary occlusion intervention procedural success score from the 20,000-patient EuroCTO registry. JACC Cardiovasc Interv. 2019;12(4):335-342.
Fujii K, Carlier SG, Mintz GS, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation. JACC. 2005;45(7):995-998.
Tajti P, Karmpaliotis D, Alaswad K, et al. Prevalence, presentation and treatment of ‘balloon undilatable’ chronic total occlusions: insights from a multicenter US registry. Catheter Cardiovasc Interv. 2018;91(4):657-666.
Improta R, Scarparo P, Wilschut J, et al. Elastic stent recoil in coronary total occlusions: comparison of durable-polymer zotarolimus eluting stent and ultrathin strut bioabsorbable-polymer sirolimus eluting stent. Catheter Cardiovasc Interv. 2022;99(1):88-97.
Kato Y, Iwata A, Nakamura M, Miura S, Saku K. In-stent restenosis due to stent recoil after third-generation drug-eluting stent implantation. J Clin Med Res. 2017;9(6):534-538.
von Birgelen C, Zocca P, Buiten RA, et al. Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. Lancet. 2018;392(10154):1235-1245.
Kandzari DE, Koolen JJ, Doros G, et al. Ultrathin bioresorbable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents. JACC Cardiovasc Interv. 2022;15(18):1852-1860.
Kandzari DE, Koolen JJ, Doros G, et al. Ultrathin bioresorbable-polymer sirolimus-eluting stents versus thin durable-polymer everolimus-eluting stents for coronary revascularization. JACC Cardiovasc Interv. 2020;13(11):1343-1353.
Buiten RA, Ploumen EH, Zocca P, et al. Thin, very thin, or ultrathin strut biodegradable or durable polymer-coated drug-eluting stents. JACC Cardiovasc Interv. 2019;12(17):1650-1660.
Kok MM, Zocca P, Buiten RA, et al. Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial. EuroIntervention. 2018;14(8):915-923.
Teeuwen K, van der Schaaf RJ, Adriaenssens T, et al. Randomized multicenter trial investigating angiographic outcomes of hybrid sirolimus-eluting stents with biodegradable polymer compared with everolimus-eluting stents with durable polymer in chronic total occlusions. JACC Cardiovasc Interv. 2017;10(2):133-143.
Wilgenhof A, Zivelonghi C, Teeuwen K, et al. Very long-term outcome of the PRISON-IV trial: 5-year clinical follow-up of ultra-thin struts in CTO-PCI. Cardiovasc Revasc Med. 2023;46:117-118.
Zivelonghi C, Agostoni P, Teeuwen K, et al. 3-year clinical outcomes of the PRISON-IV trial. JACC Cardiovasc Interv. 2019;12(17):1747-1749.
Madhavan MV, Tarigopula M, Mintz GS, Maehara A, Stone GW, Généreux P. Coronary artery calcification. JACC. 2014;63(17):1703-1714.
Ng J, Foin N, Ang HY, et al. Over-expansion capacity and stent design model: an update with contemporary DES platforms. Int J Cardiol. 2016;221:171-179.
Bonin M, Guerin P, Olive JM, Jordana F, Huchet F. Standardized bench test evaluation of coronary stents: biomechanical characteristics. Catheter Cardiovasc Interv. 2018;92(7):E465-E470.
Galassi AR, Werner GS, Boukhris M, et al. Percutaneous recanalisation of chronic total occlusions: 2019 consensus document from the EuroCTO Club. EuroIntervention. 2019;15(2):198-208.
Ybarra LF, Rinfret S, Brilakis ES, et al. Definitions and clinical trial design principles for coronary artery chronic total occlusion therapies: CTO-ARC consensus recommendations. Circulation. 2021;143(5):479-500.
Onuma Y, Serruys PW, Gomez J, et al. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv. 2011;78(1):3-12.
Isaaz K, Gerbay A, Terreaux J, et al. Restenosis after percutaneous coronary intervention for coronary chronic total occlusion. the central role of an optimized immediate post-procedural angiographic result. Int J Cardiol. 2016;224:343-347.
Sato T, Goto S, Yuasa S, Akazawa K, Aizawa Y. Predictors and outcomes of acute recoil after ultrathin bioresorbable polymer sirolimus-eluting stents implantation: an intravascular ultrasound in native coronary arteries. Coron Artery Dis. 2022;33(1):18-24.
Aziz S, Morris JL, Perry RA, Stables RH. Stent expansion: a combination of delivery balloon underexpansion and acute stent recoil reduces predicted stent diameter irrespective of reference vessel size. Heart. 2006;93(12):1562-1566.
Mintz GS, Popma JJ, Pichard AD, et al. Patterns of calcification in coronary artery disease. A statistical analysis of intravascular ultrasound and coronary angiography in 1155 lesions. Circulation. 1995;91(7):1959-1965.
Wang X, Matsumura M, Mintz GS, et al. In vivo calcium detection by comparing optical coherence tomography, intravascular ultrasound, and angiography. JACC Cardiovasc Imaging. 2017;10(8):869-879.